期刊文献+

2-羟基戊二酸对胶质母细胞瘤细胞增殖和迁移的影响

Effect of 2-hydroxyglutarate on cell proliferation and migration of human glioblastoma cells
下载PDF
导出
摘要 目的探讨2-羟基戊二酸(2-HG)对异柠檬酸脱氢酶(IDH)野生型胶质母细胞瘤增殖、迁移的作用。方法通过细胞培养,细胞增殖实验(CCK-8)检测不同浓度(5、10、15、20、30、40 mmol/L)2-HG对胶质瘤细胞的增殖抑制作用,细胞迁移实验检测细胞迁移能力,聚合酶链式反应(PCR)检测相关基因mRNA的表达。结果外源性加入2-HG使胶质母细胞瘤细胞形态发生间质样改变,随浓度的升高作用愈明显,呈浓度依赖性,促进胶质母细胞瘤细胞的增殖和迁移,下调上皮细胞标志物E-钙黏蛋白(E-Cadherin)的表达,上调间质细胞标志物波形蛋白(Vimentin)和β-链蛋白(β-catenin)的表达。结论 2-HG能够促进IDH野生型胶质母细胞瘤的增殖、迁移。 Objective To investigate the effect of 2 - hydroxyglutarate (2 - HG) on proliferation and migration of isocitrate dehydrogenase (IDH) wild - type glioma. Methods The wild - type glioma cells were cultured. CCK8 method was used to detect the inhibiting effects of different concentrations of 2 - HG (5, 10, 15, 20, 30, 40 retool/L) on the proliferation of glioma ceils. Cell migration test was perforned to detect the migration of glioma cells. And PCR was carried out to detect the expression of mRNA of related genes. Results Exogenous treatment of 2 - HG transformed the morphol- ogy of glioblastoma cells in concentration - dependent manner. Exogenous treatment of 2 - HG promoted the abilities of proliferation and migration, down -regulated the epithelial cell marker E -cadherin, and up -regulated the mesenchymal cell marker vimentin and β - catenin. Conclusion 2 - HG can promote the proliferation and migration of IDH wild - type glioblastoma cells.
出处 《广东医学》 CAS 北大核心 2017年第13期1953-1956,共4页 Guangdong Medical Journal
基金 广东省自然科学基金资助项目(编号:2014A030310008)
关键词 2-羟基戊二酸 胶质母细胞瘤 异柠檬酸脱氢酶 增殖 迁移 2-HG glioblastoma IDH proliferation migration
  • 相关文献

参考文献2

二级参考文献18

  • 1Oermann EK, Wu J, Guan KL, Xiong Y. Alterations of metabolic genes and metabolites in cancer. Semin Cell Dev Bio12012; 23:370-380.
  • 2Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. NEngl J Med 2009; 360:765-773.
  • 3Zhao S, Lin Y, Xu W, et al. Glioma- derived mutations in IDH1 domi- nantly inhibit IDH1 catalytic activity and induce HIF-lalpha. Science 2009; 324:261-265.
  • 4Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462:739-744.
  • 5Xu W, Yang H, Liu Y, et al. Oncome- tabolite 2-hydroxyglutarate is a com- petitive inhibitor of alpha-ketoglu- tarate-dependent dioxygenases. Cancer Cell2011; 19:17-30.
  • 6Chowdhury R, Yeoh KK, Tian YM, et al. The oncometabolite 2-hydroxyglu- tarate inhibits histone lysine demethy- lases. EMBO Rep 2011; 12:463-469.
  • 7Noushmehr H, Weisenberger D J, Dief- es K, et aI. Identification of a CpG is- land methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17:510-522.
  • 8Turcan S, Rohle D, Goenka A, et al. 1DH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483:479-483.
  • 9Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mu- tations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18:553-567.
  • 10Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethyla- tion and results in a block to cell differ- entiation. Nature 2012; 483:474-478.

共引文献327

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部